Edison Issues Report On Amoéba (ALMIB)
Amoéba is ready to launch its innovative and patented WmCM amoeba lysate active ingredient into the vast crop protection and anti-ageing skincare cosmetics markets. Excellent field trial results, combined with regulatory tailwinds, as consumers reduce their use of traditional chemical products, strongly support future growth. With key distribution partnerships in place, Amoéba should witness superior growth in the coming years. It has raised €9m in cash and executed a €5m debt-for-equity swap with support from key shareholder Nice & Green and distribution partner Koppert. We value Amoéba at €2.01 per share.
Click here to read the full report.
All reports published by Edison are available to download free of charge from its website.
Edison is authorised and regulated by the Financial Conduct Authority .
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- 1Inch Unlocks Access To Tokenized Rwas Via Swap API
- What Is The Growth Rate Of The Europe Baby Food And Infant Formula Market In 2025?
- BTCC Announces Participation In Token2049 Singapore 2025, Showcasing NBA Collaboration With Jaren Jackson Jr.
- Ecosync & Carboncore Launch Full Stages Refi Infrastructure Linking Carbon Credits With Web3
- New Silver Launches In California And Boston
- United States Fin Fish Market Size Forecast With Demand Outlook 20252033
Comments
No comment